Europe Ripe For Broader Biologic Use In Inflammatory Conditions
This article was originally published in Scrip
Executive Summary
The uptake in Europe of biosiomilar infliximab (versions of Janssen's blockbuster Remicade) for inflammatory diseases like rheumatoid arthritis and psoriasis has been patchy to date. In some countries of northern Europe, notably Norway, Denmark and the Netherlands, the biosimilar has been embraced and is capturing the large part of the infliximab market. In other parts of Europe, such as the UK, biosimilar developers report frustration at the lack of movement from the branded product.
You may also be interested in...
Biosimilar Infliximab Success Paves The Way For Adalimumab In Europe
With the impending European launch of Humira biosimilar adalimumab in October, Scrip talks to some of those in the region that have experience in launching commercially successful biosimilars about uptake, discounts and payer attitudes.
Biosimilar Infliximab Success Paves The Way For Adalimumab In Europe
With the impending European launch of Humira biosimilar adalimumab in October, Scrip talks to some of those in the region that have experience in launching commercially successful biosimilars about uptake, discounts and payer attitudes.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.